China Pharma Market Development Examined in New Report Published at MarketPublishers.com

Share Article

Where is the pharmaceutical market in China heading? How will governmental reform of the healthcare system affect the pharmaceutical industry? Answers to these critical questions and many more can be found in the research report “Chinese Pharmaceutical Market 2012-2022” drawn up by Visiongain and recently published by Market Publishers Ltd.

marketpublishers.com

Market Publishers Ltd

Where is the pharmaceutical market in China heading? How will governmental reform of the healthcare system affect the pharmaceutical industry? Will patented branded products achieve greater market penetration this decade? Answers to these critical questions and many more can be found in the research report.

New research report “Chinese Pharmaceutical Market 2012-2022” drawn up by Visiongain has been recently published by Market Publishers Ltd.

Report Details:

Title: Chinese Pharmaceutical Market 2012-2022
Published: December 6, 2011
Pages: 158
Price: US$ 2,642
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/chinese_pharmaceutical_market_2012_2022.html

The research report gives an independent and unbiased insight into the Chinese pharmaceutical market’s development over the next decade. Its scope comprises:

  •     revenue predictions to 2022 for the overall Chinese pharma market and submarkets, seeing potential revenue growth;
  •     profiles of 40 prominent companies, along with their developments in biotechnology and other aspects of medicine;
  •     competition and opportunities influencing sales results;
  •     overview of drivers and restrains, affecting the market’s growth;
  •     emerging trends in biopharma R&D, contract research and manufacturing;
  •     appraisal of therapeutic and commercial needs, as well as healthcare policy;
  •     opinions from the survey of authorities on the sector.

Report Contents:

1. Executive Summary

1.1 China: Pharmaceutical Market Review
1.2 Contents of this Report
1.3 Research and Analysis Methods

2. Chinese Pharmaceutical Market: an Overview

2.1 China: National Overview
2.1.1 China's Rise as an Economic Superpower
2.2 From Maoism to Market: Chinese Healthcare Since World War II
2.2.1 Socialised Healthcare
2.2.2 Developments Since 1992
2.2.3 Investment, But Healthcare Disparities Remain
2.3 The Rise of the Chinese Pharmaceutical Market
2.3.1 Picking up the Tab
2.4 Healthy China 2020: 'Unprecedented in Human History'
2.4.1 Achievements and Potential of the Healthy China 2020 Initiative
2.5 Demography and Disease Burden in China
2.5.1 The Ageing Population
2.5.2 Obesity in China
2.5.3 Stroke, Heart Disease and Diabetes
2.5.4 Cancer and Respiratory Diseases
2.5.5 Communicable Diseases
2.6 Other Aspects of the Chinese Market

3. The Chinese Pharmaceutical Market, 2012-2022

3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022
3.2 The Product Mix in China, 2010
3.3 The Product Mix in China, 2012-2022
3.4 Prescribed Patented Brands: Forecast, 2012-2022
3.4.1 Drivers and Restraints for Patented Prescription Drugs
3.5 Prescribed Generics: Forecast, 2012-2022
3.5.1 Drivers and Restraints for Prescribed Generics
3.6 OTC Products: Forecast, 2012-2022
3.6.1 Drivers and Restraints for OTC Products
3.7 TCM Products: Forecast, 2012-2022
3.7.1 Drivers and Restraints for TCM Products

4. Leading Therapeutic Areas in the Chinese Market, 2012-2022

4.1 Anti-Infectives Market, 2012-2022
4.1.1 Antibiotics: China's Drugs of Choice
4.1.2 Antivirals: a Growth Area
4.2 Cancer Treatments Market, 2012-2022
4.2.1 Small Molecules Dominate the Chinese Cancer Drug Market
4.3 Cardiovascular/Cerebrovascular Market, 2012-2022
4.3.1 Anti-Aggregants, Statins and Vasotherapeutics
4.4 Alimentary and Metabolic Diseases Market, 2012-2022
4.4.1 Antiulcerants and Diabetes Treatments
4.5 Central Nervous System Diseases Market, 2012-2022
4.5.1 Pain Relief
4.5.2 Anti-Depressants
4.5.3 Neurodegenerative Diseases
4.6 Vaccines Market, 2012-2022
4.6.1 Opportunities and Challenges in Vaccines
4.7 Other Therapeutic Classes Market, 2012-2022

5. China as a Pharmaceutical Hub, 2012-2022

5.1 China as a Manufacturing Hub
5.1.1 China's API Export Market
5.1.2 Contract Manufacturing Organisations: Beyond APIs
5.2 China as a Research Hub
5.2.1 Clinical Trials in China
5.2.2 The Rise of China's Contract Research Organisations
5.3 China as a Biotechnology Hub
...

More new research reports by the publisher can be found at Visiongain page.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website